Mesoblast Limited (MESO, MSB.AX) said that the U.S. Food and Drug Administration has granted its second generation allogeneic, ...

Mesoblast Ltd (ASX: MSB) shares are under pressure today despite some big news. What's going on with this share?

Mesoblast (MESO) announced the United States FDA has granted its second generation allogeneic, STRO3-immunoselected, and industrially ...

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target ...

Mesoblast (MESO) has released an update. Mesoblast Limited has issued 2 million unquoted warrants as part of a US$50 million convertible note facility, which the company can utilize following FDA ...

FDA granted REVASCOR both Rare Pediatric Disease Designation (RPDD) and Orphan-Drug Designation (ODD) for congenital heart diseaseNEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq:MESO; ASX:MSB), ...

Mesoblast is also testing remestemcel-L in a phase 3 trial in up to 300 ventilatory-dependent adults with moderate to severe acute respiratory distress (ARDS) due to COVID-19.

在一场令人瞩目的市场韧性展示中，Mesoblast Ltd股票已飙升至52周高点，达到12.19美元的价格水平。该股票市值为13.7亿美元，贝塔系数为2.34，显示出显著的波动性。根据 InvestingPro 数据，分析师的目标价格范围从11美元到18美元不等，暗示可能存在上涨空间。这一重要里程碑凸显了这家生物制药公司强劲增长的时期，其股票价值年初至今已飙升了惊人的432.73%。投资者对Mes ...

These shares are having a tough time on Thursday. What's going on? The post Why 29Metals, Guzman Y Gomez, Mesoblast, and Pilbara Minerals shares are falling today appeared first on The Motley Fool ...